07:00 , May 14, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-28A (IL-28A; IFNL2); interferon (IFN) λ receptor (IL28RA; IFNLR1)

Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Studies in mice suggest that IL-28A or IL28RA agonists could help treat RA and other neutrophil-mediated inflammatory diseases. IL28RA was highly expressed on circulating neutrophils in a mouse model of RA...
07:00 , May 19, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Rotavirus Interferon-l receptor (IL28RA; IFNLR1); IL-28A (IFNL2) Mouse studies suggest promoting...
07:00 , Sep 13, 2004 |  BC Week In Review  |  Company News

Serono SA, ZymoGenetics deal

ZGEN granted SEO access to a portfolio of genes and proteins for evaluation, screening and licensing. SEO also received rights to license up to 12 products from ZGEN's internal research projects. ZGEN will have an...
07:00 , Sep 13, 2004 |  BioCentury  |  Strategy

Protein payoff

Last week's deal between ZymoGenetics Inc. and Serono S.A. is a matter of productivity, giving ZGEN the opportunity to monetize the downstream value of its prolific research, while allowing the Swiss biopharmaceutical company to bulk...
07:00 , Sep 13, 2004 |  BioCentury  |  Strategy

Preclinical deal comps

Preclinical deal comps Seller/Buyer (Disease area) Potential value Mile stones Upfront/ Equity R&D funding Sales upside Abgenix/Astra Zeneca (Cancer) ND ND $100.0 Abgenix funds early trials, AstraZeneca funds the rest Royalties, profit sharing Two-stage...
07:00 , Sep 8, 2004 |  BC Extra  |  Top Story

ZGEN, Serono biologics R&D deal

Under a five-year deal, ZymoGenetics (ZGEN) granted Serono (SWX:SEO; SRA) access to a portfolio of genes and proteins for evaluation, screening and licensing for a total of $81.3 million in upfront payments and an equity...
07:00 , Jul 12, 2004 |  BC Week In Review  |  Company News

ZymoGenetics, Novo Nordisk deal

ZymoGenetics Inc. (ZGEN), Seattle, Wash.   Novo Nordisk A/S (NVO), Bagsvaerd, Denmark   Business: Infectious, Inflammation   ZGEN granted NVO exclusive development rights outside North America to three proteins: interleukin 28A (IL-28A), interleukin 29 (IL-29)...
07:00 , Jul 6, 2004 |  BC Extra  |  Company News

ZymoGenetics, NVO interleukin deal

ZGEN granted Novo Nordisk (NVO) exclusive development rights outside North America to three proteins: interleukin 28A (IL-28A), interleukin 29 (IL-29) and interleukin 31 (IL-31). ZGEN said IL-28A and IL-29 have shown antiviral activity and are...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Company News

ZymoGenetics other research news

Researchers published in Nature Immunology the identification IL-28A, IL-28B and IL-29 that are distantly related to type I interferons and IL-10. IL-28 and IL-29 were induced by viral infection and showed antiviral activity. IL-28 and...